Publications
| Title | Abstract | Year(sorted descending) Filter | PMID Filter |
|---|
| phenotype and hierarchy of two transgenic t cell lines targeting the respiratory syncytial virus kdm282-90 epitope is transfer dose-dependent. | in this study, we compared two lines of transgenic cd8+ t cells specific for the same kdm282-90 epitope of respiratory syncytial virus in the cb6f1 hybrid mouse model. here we found that these two transgenic lines had similar in vivo abilities to control viral load after respiratory syncytial virus infection using adoptive transfer. transfer of the trbv13-2 line resulted in higher levels of il-6 and mip1-α in the lung than trbv13-1 transfer. interestingly, when large numbers of cells were co-tra ... | 2016 | 26752171 |
| a population study of respiratory rehospitalisation in very preterm infants in the first 3 years of life. | very premature infants consume healthcare resources following discharge from neonatal intensive care units (nicu). this study aimed to evaluate the burden of respiratory related rehospitalisation within the first 3 years post discharge in very premature infants in an australian population. | 2016 | 27203818 |
| double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. | more active high-dose chemotherapy (hdc) regimens are needed for refractory lymphomas. the authors previously combined infusional gemcitabine with busulfan and melphalan (gem/bu/mel) pursuing dna damage repair inhibition. subsequently, they combined gem/bu/mel with vorinostat, which facilitates chemotherapy access to dna. the resulting regimen was safe and synergistic. however, vorinostat induced dna methyltransferase up-regulation, which could be preclinically abrogated by azacitidine, increasi ... | 2016 | 27203405 |
| outbreak of respiratory syncytial virus (rsv) infection in immunocompromised adults on a hematology ward. | we describe an outbreak of respiratory syncytial virus (rsv) infection on a hematology ward without allogeneic stem cell transplant patients. twelve patients and one staff member infected with rsv were identified from the laboratory database. five patients had lower respiratory tract infection, seven had upper respiratory tract infection, one was asymptomatic, and there were two (15.4%) deaths. most patients had overlapping periods of potential infectiousness on the ward. sequencing was possible ... | 2016 | 26990584 |
| determinants of early life immune responses to rsv infection. | respiratory syncytial virus causes significant morbidity and mortality in both developed and developing countries, and a vaccine that adequately protects from severe disease remains an important unmet need. rsv disease has an inordinate impact on the very young, and the physical and immunological immaturity of early life complicates vaccine design. defining and targeting the functional capacities of early life immune responses and controlling responses during primary antigen exposure with select ... | 2016 | 26986236 |
| performance evaluation of four rapid antigen tests for the detection of respiratory syncytial virus. | rapid identification of respiratory syncytial virus (rsv) is important in the management of infected patients. rapid diagnostic tests (rdt) are widely used for this purpose. this study aimed to evaluate the clinical performance of four rsv antigen tests including the binaxnow rsv card test, sd bioline rsv test, bd veritor rsv test, and humasis rsv antigen test in comparison with real-time rt-pcr as the reference method. nasopharyngeal swabs were collected from 280 patients with symptoms of lower ... | 2016 | 26990654 |
| human cathelicidin, ll-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells. | respiratory syncytial virus (rsv) is a major cause of severe lower respiratory tract illness in young children worldwide. treatment options for severe rsv disease remain limited and the development of therapeutic treatment strategies remains a priority. ll-37, a small cationic host defense peptide involved in anti-inflammatory and anti-bacterial responses, reduces replication of or infection by multiple viruses, including influenza virus, in vitro, and protects against lethal challenge with infl ... | 2016 | 26732674 |
| outcomes of respiratory syncytial virus immunoprophylaxis in infants using an abbreviated dosing regimen of palivizumab. | 2016 | 26720836 | |
| antiviral activity of the "virus blocking factor" (vbf) derived i.a. from pelargonium extract and sambucus juice against different human-pathogenic cold viruses in vitro. | the in-vitro antiviral activity of the "virus blocking factor" (vbf), a combination of pelargonium extract and sambucus juice with addition of betaglucan 1,3 / 1,6, zincum gluconium, acidum ascorbicum, was studied against human pathogenic viruses: influenza a h1n1 (flua h1n1), rhinovirus b subtype 14 (hrv14), respiratory syncytial virus (rsv), parainfluenzavirus subtype 3 (para 3), and adenovirus c subtype 5 (adeno 5). | 2016 | 28478414 |
| progress toward a respiratory syncytial virus vaccine. | in accompanying papers (p. l. acosta, m. t. caballero, and f. p. polack, clin vaccine immunol 23:189-195, 2016, http://dx.doi.org/10.1128/cvi.00609-15; m. vissers, i. m. l. ahout, m. i. de jonge, and g. ferwerda, clin vaccine immunol 23:243-245, 2016, http://dx.doi.org/10.1128/cvi.00590-15) in this issue of clinical and vaccine immunology, the history of and immune mechanisms underlying vaccine-enhanced respiratory syncytial virus (rsv) disease and of investigations of mucosal antibodies and the ... | 2016 | 26818954 |
| angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. | respiratory syncytial virus (rsv) infection is a major cause of severe lower respiratory illness in infants and young children, but the underlying mechanisms responsible for viral pathogenesis have not been fully elucidated. to date, no drugs or vaccines have been employed to improve clinical outcomes for rsv-infected patients. in this paper, we report that angiotensin-converting enzyme-2 (ace2) protected against severe lung injury induced by rsv infection in an experimental mouse model and in p ... | 2016 | 26813885 |
| protein tyrosine phosphatase 1b negatively regulates s100a9-mediated lung damage during respiratory syncytial virus exacerbations. | protein tyrosine phosphatase 1b (ptp1b) has anti-inflammatory potential but ptp1b responses are desensitized in the lung by prolonged cigarette smoke exposure. here we investigate whether ptp1b expression affects lung disease severity during respiratory syncytial viral (rsv) exacerbations of chronic obstructive pulmonary disease (copd). ptp1b(-/-) mice infected with rsv exhibit exaggerated immune cell infiltration, damaged epithelial cell barriers, cytokine production, and increased apoptosis. e ... | 2016 | 26813343 |
| fas-associated factor 1 negatively regulates the antiviral immune response by inhibiting translocation of interferon regulatory factor 3 to the nucleus. | this study is designed to examine the cellular functions of human fas-associated factor 1 (faf1) containing multiple ubiquitin-related domains. microarray analyses revealed that interferon-stimulated genes related to the antiviral response are significantly increased in faf1-knockdown hela cells. silencing faf1 enhanced the poly(i·c)- and respiratory syncytial virus (rsv)-induced production of type i interferons (ifns), the target genes of interferon regulator factor 3 (irf3). irf3 is a key tran ... | 2016 | 26811330 |
| respiratory syncytial virus: a byzantine pathogen. | 2016 | 26795683 | |
| a recombinant g protein plus cyclosporine a-based respiratory syncytial virus vaccine elicits humoral and regulatory t cell responses against infection without vaccine-enhanced disease. | respiratory syncytial virus (rsv) infection can cause severe disease in the lower respiratory tract of infants and older people. vaccination with a formalin-inactivated rsv vaccine (fi-rsv) and subsequent rsv infection has led to mild to severe pneumonia with two deaths among vaccinees. the vaccine-enhanced disease (ved) was recently demonstrated to be due to an elevated level of th2 cell responses following loss of regulatory t (treg) cells from the lungs. to induce high levels of neutralizing ... | 2016 | 26792805 |
| evidence for a biphasic mode of respiratory syncytial virus transmission in permissive hep2 cell monolayers. | during respiratory syncytial virus (rsv) infection filamentous virus particles are formed on the cell surface. although the virus infectivity remains cell-associated, low levels of cell-free virus is detected during advanced infection. it is currently unclear if this cell-free virus infectivity is due to a low-efficiency specific cell-release mechanism, or if it arises due to mechanical breakage following virus-induced cell damage at the advanced stage of infection. understanding the origin of t ... | 2016 | 26790623 |
| development of acquired immunity following repeated respiratory syncytial virus infections in cotton rats. | respiratory syncytial virus (rsv) infections occur every year worldwide. most infants are infected with rsv by one year of age and are reinfected because immune responses after the first infection are too weak to protect against subsequent infections. in the present study, immune responses against rsv were investigated in order to obtain a better understanding of repetitive rsv infections in cotton rats. no detectable neutralizing antibody (nt) was developed after the first infection, and the se ... | 2016 | 27224021 |
| vaccines against respiratory syncytial virus: the time has finally come. | respiratory syncytial virus causes a significant public health burden, particularly in very young infants and the frail elderly. the legacy of enhanced rsv disease (erd) from a whole formalin-inactivated rsv vaccine, and the complex biology of the virus and the neonate have delayed the development of effective vaccines. however, new insights into factors associated with erd and breakthroughs in understanding the antigenic structure of the fusion (f) glycoprotein have increased optimism that vacc ... | 2016 | 27182820 |
| morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review. | previous studies have demonstrated high morbidity and mortality for adult patients with respiratory syncytial virus (rsv) infection. we performed a retrospective, multicenter, two-year chart review of all patients (n = 334) testing positive for rsv by the proflu + (®) influenza a/b and rsv assay (hologic, bedford, ma). we analyzed indicators of morbidity and mortality in children <6 years old, immunocompetent and immunosuppressed adults, and transplant patients. significant morbidity and mortali ... | 2016 | 27179369 |
| enhanced allergic responsiveness after early childhood infection with respiratory viruses: are long-lived alternatively activated macrophages the missing link? | early childhood infection with respiratory viruses, including human rhinovirus, respiratory syncytial virus (rsv) and influenza, is associated with an increased risk of allergic asthma and severe exacerbation of ongoing disease. despite the long recognition of this relationship, the mechanism linking viral infection and later susceptibility to allergic lung inflammation is still poorly understood. we discuss the literature and provide new evidence demonstrating that these viruses induce the alte ... | 2016 | 27178560 |
| respiratory viruses and children. | respiratory viruses place a great disease burden especially on the youngest children in terms of high rates of infection, bacterial complications and hospitalizations. in developing countries, some viral infections are even associated with substantial mortality in children. the interaction between viruses and bacteria is probably much more common and clinically significant than previously understood. respiratory viruses frequently initiate the cascade of events that ultimately leads to bacterial ... | 2016 | 27177731 |
| a regional cohort study of the treatment of critically ill children with bronchiolitis. | to describe the treatment practices in critically ill children with rsv bronchiolitis across four regional picus in the northeastern united states, and to determine the factors associated with increased icu length of stay in this population. | 2016 | 27177013 |
| nasopharyngeal microbiome in respiratory syncytial virus resembles profile associated with increased childhood asthma risk. | 2016 | 27174483 | |
| the burden of severe respiratory syncytial virus disease among children younger than 1 year in central and eastern europe. | globally, respiratory syncytial virus (rsv) is the most common cause of serious lower respiratory tract infections (lrtis) in young children, and is a major cause of hospital admission in children <1 year of age. the study evaluated the severity of rsv-associated lrti disease among premature (<36 weeks gestational age (ga)) and term children <1 year of age and assessed the influence of ga on outcomes of rsv lrti hospitalization in central and eastern europe (cee). | 2016 | 27174177 |
| biochemical effect of resistance mutations against synergistic inhibitors of rsv rna polymerase. | als-8112 is the parent molecule of als-8176, a first-in-class nucleoside analog prodrug effective in the clinic against respiratory syncytial virus (rsv) infection. the antiviral activity of als-8112 is mediated by its 5'-triphosphate metabolite (als-8112-tp, or 2'f-4'clch2-cytidine triphosphate) inhibiting the rna polymerase activity of the rsv l-p protein complex through rna chain termination. four amino acid mutations in the rna-dependent rna polymerase (rdrp) domain of l (quad: m628l, a789v, ... | 2016 | 27163448 |
| [recommendations for palivizumab use. update 2015]. | this recommendation updates the argentinean pediatrics' neonatal committee (cefen) ones published in 2007. the respiratory syncytial virus is the most frequent agent for lower respiratory infection. tiny premature, bronchopulmonary dysplasia and significant hemodynamic congenital heart disease babies are the most vulnerable populations. palivizumab is a humanized monoclonal antibody against respiratory syncytial virus used in the cold season. these recommendations are based on the scientific rev ... | 2016 | 26914078 |
| paediatric apnoeas are not related to a specific respiratory virus, and parental reports predict hospitalisation. | the aim of this study was to determine the frequency of apnoeas in previously healthy young infants with acute respiratory tract infection (ari) and correlate their occurrence with isolated micro-organisms, clinical findings, disease severity and outcome. | 2016 | 26910649 |
| effect of co-culturing human primary basic fibroblasts with respiratory syncytial virus-infected 16-hbe cells. | this study investigated the effects induced by co-culturing human primary basic fibroblasts (hpbfs) with 16-human bronchial epithelial cells (16-hbe) infected with respiratory syncytial virus (rsv), in particular the transformation of hpbfs into myofibroblasts and secretion of extracellular matrix proteins. hpbfs were co-cultured with 16-hbe cells infected with rsv and quantitatively analyzed. we constructed models of hpbfs co-cultured with 16-hbe cells that were either uninfected (control group ... | 2016 | 26909955 |
| corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. | respiratory syncytial virus (rsv) infection causes significant morbidity and mortality in allogeneic stem cell transplant (allo-sct) recipients. although ribavirin and immunoglobulins are common components of therapy, the role of adjunct corticosteroids is not established. | 2016 | 26909896 |
| atypical presentations of respiratory syncytial virus infection: case series. | the respiratory syncytial virus (rsv) usually causes a lower respiratory tract infection in affected patients. rsv has also been infrequently linked to extrapulmonary diseases in children. we report four children who had unusually severe clinical manifestations of rsv infections requiring critical care admission. these patients presented to the royal hospital, muscat, oman, in december 2013 with acute necrotising encephalopathy (ane), acute fulminant hepatic failure with encephalopathy, pneumato ... | 2016 | 26909220 |
| clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children. | immunocompromised patients are at high risk for morbidity and mortality due to respiratory syncytial virus (rsv) infection. increasingly, pediatric patients with malignancy or undergoing transplantation are managed primarily as outpatients. data regarding the clinical presentation and outcomes of rsv in the outpatient pediatric immunocompromised population are limited. | 2016 | 26859306 |
| burden of influenza and respiratory syncytial virus infection in pregnant women and infants under 6 months in mongolia: a prospective cohort study. | pregnant women and infants under 6 months are at risk of influenza-related complications. limited information exists on their community burden of respiratory viruses. | 2016 | 26849042 |
| erratum: effect of prophylactic palivizumab on admission due to respiratory syncytial virus infection in former very low birth weight infants with bronchopulmonary dysplasia. | 2016 | 26839492 | |
| chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. | this cochrane review was first published in 2005 and updated in 2007, 2012 and now 2015. acute bronchiolitis is the leading cause of medical emergencies during winter in children younger than two years of age. chest physiotherapy is sometimes used to assist infants in the clearance of secretions in order to decrease ventilatory effort. | 2016 | 26833493 |
| evaluation of a fluorescent immunoassay rapid test (sofia™) for detection of influenza a+b and rsv in a tertiary pediatric setting. | in response to the lack of sensitivity and reproducibility of previously marketed rapid antigen detection tests, a novel fluorescent immunoassay was recently developed. this new assay offers rapidity and automated reading. more characterization of this assay is needed. the aim of this study was to assess diagnostic performance of sofia influenza a+b and respiratory syncytial virus (rsv) while compared to traditional viral cell culture. a total of 416 respiratory samples were analyzed prospective ... | 2016 | 26827091 |
| risk of respiratory syncytial virus infection in cyanotic congenital heart disease in a subtropical area. | to compare the risk of respiratory syncytial virus (rsv)-associated hospitalization and analyze the epidemiology of rsv infection in patients with cyanotic and acyanotic congenital heart disease (chd), we analyzed the nationwide health insurance database from 2005-2010. | 2016 | 26822618 |
| absence of human rhinovirus and respiratory syncytial virus from bronchoalveolar lavage and bronchial biopsies of selected patients with stable chronic obstructive pulmonary disease. | previous studies have reported very different rates of human rhinovirus (hrv) and respiratory syncytial virus (rsv) genome detection in nasal and sputum samples, but not in bronchoalveolar lavage (bal) and bronchial biopsy samples. our study aimed to investigate the presence of hrv and rsv in the lungs of 31 consecutive patients with stable copd (11 gold stage i, 11 ii, and 9 iii) and 22 control subjects (12 current or past smokers, and 10 non-smokers), who underwent diagnostic (e.g., lung cance ... | 2016 | 26819185 |
| contamination of healthcare workers' mobile phones by epidemic viruses. | mobile phones (mps) are potential reservoirs of nosocomial bacteria, but few data are available concerning viruses. we aimed to evaluate the presence of virus rna from epidemic viruses including metapneumovirus, respiratory syncytial virus, influenza viruses, rotavirus (rv) and norovirus on the mps used by healthcare workers (hcws) and to relate it to hygiene measures. an anonymous behavioural questionnaire about mp use at hospital was administered to the hcws of four adult and paediatric depart ... | 2016 | 26713553 |
| trends in respiratory syncytial virus bronchiolitis hospitalizations in children less than 1 year: 2004-2012. | to analyze trends in health outcomes and the influence of risk factors in children under 1 year with acute bronchiolitis due to respiratory syncytial virus (rsv bronchiolitis). a risk-adjustment model for rsv bronchiolitis in-hospital mortality was also developed. | 2016 | 26709735 |
| baculovirus vectors expressing f proteins in combination with virus-induced signaling adaptor (visa) molecules confer protection against respiratory syncytial virus infection. | baculovirus has been exploited for use as a novel vaccine vector. to investigate the feasibility and efficacy of recombinant baculoviruses (rbvs) expressing respiratory syncytial virus (rsv) fusion (f) proteins, four constructs (bac-tf/64, bac-cf, bac-cf/tf64 and bac-cf/tf64-visa) were generated. bac-tf64 displays the f ectodomain (tf) on the envelope of rbvs, whereas bac-cf expresses full-length f protein in transduced mammalian cells. bac-cf/tf64 not only displays tf on the envelope but also e ... | 2016 | 26643933 |
| rsv vaccine use--the missing data. | respiratory syncytial virus (rsv) infection is the most important cause of hospitalization in infants and is one of the leading global causes of infant mortality and as such its prevention through vaccination is a public health priority. while essential for the successful implementation of vaccine programs, there remains a paucity of data on the epidemiology of the virus in different settings and age groups and limited knowledge about virus transmission and the health-care costs of the disease. ... | 2016 | 26636902 |
| effectiveness of palivizumab in children with childhood interstitial lung disease: the french experience. | there is a lack of evidence concerning the effectiveness of immunoprophylaxis with palivizumab in children with childhood interstitial lung disease (child). in this retrospective study, we evaluated the effectiveness of palivizumab for decreasing the rate of rsv-related hospitalizations in children under the age of 24 months with child treated with corticosteroids. | 2016 | 26636747 |
| [respiratory syncytial virus outbreak in a tertiary hospital neonatal intensive care unit]. | investigation and control of a respiratory syncytial virus (rsv) outbreak that affected the neonatal intensive care unit (nicu) of a university hospital from october to december 2012. | 2016 | 26776167 |
| pre-birth cohort study of atopic dermatitis and severe bronchiolitis during infancy. | infants hospitalized for bronchiolitis (i.e. severe bronchiolitis) are at increased risk of childhood asthma. there are many known risk factors for severe bronchiolitis, including cardiac and pulmonary diseases. less is known about the association between atopic diseases and risk of severe bronchiolitis. we sought to further examine risk factors for severe bronchiolitis, focusing on atopic dermatitis (ad). | 2016 | 26766307 |
| acute respiratory infections in children and adolescents with acute lymphoblastic leukemia. | knowledge regarding the incidence, clinical course, and impact of respiratory viral infections in children with acute lymphoblastic leukemia (all) is limited. | 2016 | 26700662 |
| molecular mechanism of respiratory syncytial virus fusion inhibitors. | respiratory syncytial virus (rsv) is a leading cause of pneumonia and bronchiolitis in young children and the elderly. therapeutic small molecules have been developed that bind the rsv f glycoprotein and inhibit membrane fusion, yet their binding sites and molecular mechanisms of action remain largely unknown. here we show that these inhibitors bind to a three-fold-symmetric pocket within the central cavity of the metastable prefusion conformation of rsv f. inhibitor binding stabilizes this conf ... | 2016 | 26641933 |
| understanding respiratory syncytial virus (rsv) vaccine development and aspects of disease pathogenesis. | respiratory syncytial virus (rsv) is the most important cause of lower respiratory tract infections causing bronchiolitis and some mortality in young children and the elderly. despite decades of research there is no licensed rsv vaccine. although significant advances have been made in understanding the immune factors responsible for inducing vaccine-enhanced disease in animal models, less information is available for humans. in this review, we discuss the different types of rsv vaccines and thei ... | 2016 | 26641318 |
| flt3 ligand improves the innate response to respiratory syncytial virus and limits lung disease upon rsv reexposure in neonate mice. | respiratory syncytial virus (rsv) causes severe bronchiolitis in infants worldwide. the immunological factors responsible for rsv susceptibility in infants are poorly understood. here, we used the balb/c mouse model of neonatal rsv infection to study the mechanisms leading to severe disease upon reexposure to the virus when adults. two major deficiencies in neonatal lung innate responses were found: a poor dcs mobilization, and a weak engagement of the ifni pathway. the administration of flt3 li ... | 2016 | 26681580 |
| reduced expression of hla-dr on monocytes during severe respiratory syncytial virus infections. | respiratory syncytial virus (rsv) is a common cause of bronchiolitis in infants with a wide spectrum of disease severity. besides environmental and genetic factors, it is thought that the innate immune system plays a pivotal role. the aim of this study was to investigate the expression of immune receptors on monocytes and the in vitro responsiveness from infants with severe rsv infections. | 2016 | 26658377 |
| population-based analysis of bronchiolitis epidemiology in valencia, spain. | there is a lack of european epidemiologic population-based studies on bronchiolitis and respiratory syncytial virus (rsv) bronchiolitis including both hospitalizations and primary care attendance. | 2016 | 26658376 |
| protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin. | a desirable vaccine against respiratory syncytial virus (rsv) should induce neutralizing antibodies without eliciting abnormal t cell responses to avoid vaccine-enhanced pathology. in an approach to deliver rsv neutralizing epitopes without rsv-specific t cell antigens, we genetically engineered chimeric influenza virus expressing rsv f262-276 neutralizing epitopes in the globular head domain as a chimeric hemagglutinin (ha) protein. immunization of mice with formalin-inactivated recombinant chi ... | 2016 | 26656630 |
| antiviral benzofurans from eupatorium chinense. | eleven benzofuran dimers, (+)-dieupachinins a-e, (-)-dieupachinins a-e and dieupachinin f, a benzofuran trimer trieupachinin a, as well as seven known compounds were isolated from the roots of eupatorium chinense. the enantiomers of racemates dieupachinins a-e were separated by chiral hplc. the structures with absolute configurations were elucidated on the basis of spectroscopic data, x-ray diffraction analysis, and circular dichroism experiments. the isolated compounds were evaluated for their ... | 2016 | 26675360 |
| post-bronchiolitis use of asthma medication: a prospective 1-year follow-up study. | our aim was to evaluate the association between viral findings during bronchiolitis and the use of asthma controller medication (primary outcome) and systemic corticosteroids (secondary outcome) during the first post-bronchiolitis year. | 2016 | 26658529 |
| the logistics and coordination of respiratory syncytial virus immunoprophylaxis use among us pediatric specialists. | this study was conducted to survey us pediatric specialists about administration of respiratory syncytial virus (rsv) immunoprophylaxis, communication patterns among physicians and parents, and barriers to access. separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. most physicians (≥93.5%) routinely recommended immunoprophylaxis to high-risk children. most respondents (≥71.8%) reported that >50.0% of eligible infants and young child ... | 2016 | 26746004 |
| prospective clinical and serological follow-up in early childhood reveals a high rate of subclinical rsv infection and a relatively high reinfection rate within the first 3 years of life. | children encounter repeated respiratory tract infections during their early life. we conducted a prospective clinical and serological follow-up study to estimate the respiratory syncytial virus (rsv) primary infection and reinfection rates in early childhood. sera were collected from 291 healthy children at the ages of 13, 24 and 36 months and antibody levels against rsv antigens were determined by enzyme immunoassay. the rt-pcr method was also used for identifying the possible presence of rsv i ... | 2016 | 26732801 |
| high burden of rsv hospitalization in very young children: a data linkage study. | linked administrative population data were used to estimate the burden of childhood respiratory syncytial virus (rsv) hospitalization in an australian cohort aged <5 years. rsv-coded hospitalizations data were extracted for all children aged <5 years born in new south wales (nsw), australia between 2001 and 2010. incidence was calculated as the total number of new episodes of rsv hospitalization divided by the child-years at risk. mean cost per episode of rsv hospitalization was estimated using ... | 2016 | 26626237 |
| maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from rsv in newborn lambs. | respiratory syncytial virus (rsv) is the causative agent of serious upper and lower respiratory tract infections in newborns and infants. protection from rsv is crucial for neonates, and maternal immunization is one approach that holds promise for providing immediate protection to young infants against severe rsv infection. we previously reported efficacy of a subunit vaccine consisting of the fusion (f) protein formulated with a novel adjuvant (δf/triadj) in neonates. the goal of the current st ... | 2016 | 26616551 |
| current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the midwestern respiratory virus collaborative. | the optimal treatment for respiratory syncytial virus (rsv) infection in adult immunocompromised patients is unknown. we assessed the management of rsv and other non-influenza respiratory viruses in midwestern transplant centers. | 2016 | 26923867 |
| epidemiology of laboratory-confirmed respiratory syncytial virus infection in young children in england, 2010-2014: the importance of birth month. | the epidemiology of laboratory-confirmed respiratory syncytial virus (rsv) infections in young children has not recently been described in england, and is an essential step in identifying optimal target groups for future licensed rsv vaccines. we used two laboratory surveillance systems to examine the total number and number of positive rsv tests in children aged <5 years in england from 2010 to 2014. we derived odds ratios (ors) with 95% confidence intervals (cis) comparing children by birth mo ... | 2016 | 26916807 |
| a numerically subdominant cd8 t cell response to matrix protein of respiratory syncytial virus controls infection with limited immunopathology. | cd8 t cells are involved in pathogen clearance and infection-induced pathology in respiratory syncytial virus (rsv) infection. studying bulk responses masks the contribution of individual cd8 t cell subsets to protective immunity and immunopathology. in particular, the roles of subdominant responses that are potentially beneficial to the host are rarely appreciated when the focus is on magnitude instead of quality of response. here, by evaluating cd8 t cell responses in cb6f1 hybrid mice, in whi ... | 2016 | 26943673 |
| intrinsic disorder to order transitions in the scaffold phosphoprotein p from the respiratory syncytial virus rna polymerase complex. | intrinsic disorder is at the center of biochemical regulation and is particularly overrepresented among the often multifunctional viral proteins. replication and transcription of the respiratory syncytial virus (rsv) relies on a rna polymerase complex with a phosphoprotein cofactor p as the structural scaffold, which consists of a four-helix bundle tetramerization domain flanked by two domains predicted to be intrinsically disordered. because intrinsic disorder cannot be reduced to a defined ato ... | 2016 | 26901160 |
| spontaneous pneumothorax with subcutaneous emphysema: a rare complication of respiratory syncytial virus infection. | viral bronchiolitis is the most common lower respiratory tract infection in infants and children under the age of 2. respiratory syncytial virus (rsv) is the infecting agent in more than 50% of the cases. usually the clinical course is uneventful and complications are uncommon. secondary air leaks are a recognized rare complication of bronchiolitis, although the real incidence remains unknown. we report a case of a 21-month-old female that developed a spontaneous pneumothorax (pno) with subcutan ... | 2016 | 26858803 |
| early-life respiratory infections and asthma development: role in disease pathogenesis and potential targets for disease prevention. | this article presents recent findings and perspectives on the relationship between early-life respiratory infections and asthma inception, and discusses emerging concepts on strategies that target these infectious agents for asthma prevention. | 2016 | 26854761 |
| antibody response to respiratory syncytial virus infection in children <18 months old. | the development of a safe and effective respiratory syncytial virus (rsv) vaccine might be facilitated by knowledge of the natural immune response to this virus. the aims of this study were to evaluate the neutralizing antibody response of a cohort of healthy children <18 months old to rsv infection. during the rsv season, 89 healthy children <18 months old were enrolled and followed up weekly for 12 weeks. at each visit, a nasopharyngeal swab was obtained for rsv detection by real-time polymera ... | 2016 | 26901128 |
| naso-pharyngeal carriage of organisms in children aged 3-59 months diagnosed with severe community-acquired pneumonia. | to study the naso-pharyngeal carriage of organisms in children diagnosed with severe pneumonia. | 2016 | 26897143 |
| vitamin d [1,25(oh)2d3] differentially regulates human innate cytokine responses to bacterial versus viral pattern recognition receptor stimuli. | vitamin d plays multiple roles in regulation of protective and maladaptive immunity. although epidemiologic studies link poor in vivo 25(oh)d status to increased viral respiratory infections, we poorly understand how vitamin d affects viral pattern recognition receptor (prr)-driven cytokine production. in this study, we hypothesized that the biologically active metabolite of vitamin d, 1,25(oh)2d3, inhibits human proinflammatory and anti-inflammatory innate cytokine responses stimulated by repre ... | 2016 | 26895836 |
| do recombinant-engineered nanoparticle vaccines hold promise for the prevention of respiratory syncytial virus? | 2016 | 26893211 | |
| respiratory syncytial virus - more chimera than chimpanzee? | 2016 | 26906878 | |
| evidence of respiratory syncytial virus spread by aerosol. time to revisit infection control strategies? | respiratory syncytial virus (rsv) is a highly contagious pathogen with a huge global health impact. it is a major cause of hospital-acquired infection; a large number of those exposed develop infection. those infected in hospital are at increased risk of a severe clinical course. prevention of nosocomial spread currently focuses on spread by hand and large droplets. there is little research evidence to determine if aerosol spread of infectious rsv is possible. | 2016 | 26890617 |
| evaluation of recent new vaccine surveillance network data regarding respiratory syncytial virus hospitalization rates in us preterm infants. | in july 2014, the committee on infectious diseases (coid) updated their guidance on the use of palivizumab, recommending against use in preterm infants 29 to 35 weeks' gestational age (wga). a primary data source cited to support this significant change was the low respiratory syncytial virus (rsv) hospitalization rate observed in the subpopulation of preterm (<37 wga) infants evaluated from 2000 to 2005 through the new vaccine surveillance network (nvsn). here we critically appraise the preterm ... | 2016 | 26889568 |
| epidemic activity of respiratory syncytial virus is related to temperature and rainfall in equatorial tropical countries. | although viral acute lower respiratory infections (alris) are a major public health problem in tropical low- and middle-income countries (lmics), and there is growing evidence showing their relationship with meteorological parameters, studies performed in these countries are scarce. in an analytical cross-sectional study, we determined which of the main meteorological parameters (temperature, absolute humidity, rainfall, wind speed, and solar radiation) predicted respiratory syncytial virus (rsv ... | 2016 | 26888544 |
| cytokine responses in primary and secondary respiratory syncytial virus infections. | primary respiratory syncytial virus (rsv) infections are characterized by high levels of il-8 and an intense neutrophilia. little is known about the cytokine responses in secondary infections. preschool children experiencing rsv secondary infections were recruited from the siblings of infants admitted to hospital with rsv acute bronchiolitis. | 2016 | 26882371 |
| new insight into the pathogenesis of minimal change nephrotic syndrome: role of the persistence of respiratory tract virus in immune disorders. | the pathogenesis of minimal change nephrotic syndrome (mcns) is a complex clinical problem which, unfortunately, has been in need of significant breakthroughs for decades. improved understanding of the mechanisms is important to develop effective treatment strategies. to our knowledge, the pathogenesis of mcns is multifactorial, involving both intrinsic and extrinsic factors, reasonable to be regarded as a "long chain" cascade reaction. current studies implicating that the disease could probably ... | 2016 | 26876386 |
| [lower respiratory tract infection caused by influenza virus a and influenza virus b in wenzhou, china: a clinical analysis of 366 children]. | to compare the epidemiological and clinical features of lower respiratory tract infection (lrti) caused by influenza virus a (iva) and influenza virus b (ivb) in children. | 2016 | 26903057 |
| latest options for treatment of bronchiolitis in infants. | bronchiolitis is the most frequent pathology associated with lower respiratory tract infection in newborns and young infants. the treatment of bronchiolitis is essentially supportive therapy for respiratory distress, hypoxia and dehydration. to date, no specific antiviral drug is used on a routine basis for the treatment of rsv infections. currently, the only antiviral drug approved for the infection is ribavirin; however, its use is limited due to adverse side effects and the risks it poses to ... | 2016 | 26901672 |
| risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. | respiratory syncytial virus (rsv) causes a significant public health burden, and outbreaks among vulnerable patients in hospital settings are of particular concern. we reviewed published and unpublished literature from hospital settings to assess: (i) nosocomial rsv transmission risk (attack rate) during outbreaks, (ii) effectiveness of infection control measures. we searched the following databases: medline, embase, cinahl, cochrane library, together with key websites, journals and grey literat ... | 2016 | 26901358 |
| genetic association of tlr4 asp299gly, tlr4 thr399ile, and cd14 c-159t polymorphisms with the risk of severe rsv infection: a meta-analysis. | respiratory syncytial virus (rsv) is the most frequent cause of hospitalization in infants worldwide. it is recognized by toll-like receptor 4 (tlr 4) and cluster of differentiation 14 (cd14) in the innate immune response. previous case-control studies reported the influence of tlr4 asp299gly, tlr4 thr399ile, and cd14 c-159t polymorphisms on the risk of severe rsv infection. however, a decisive conclusion has not been achieved. therefore, we performed this meta-analysis to examine the associatio ... | 2016 | 26901241 |
| children hospitalized with rhinovirus bronchiolitis have asthma-like characteristics. | children with bronchiolitis often are considered a homogeneous group. however, in a multicenter, prospective study of 2207 young children hospitalized for bronchiolitis, we found that children with respiratory syncytial virus detected differ from those with rhinovirus detected; the latter patients resemble older children with asthma, including more frequent treatment with corticosteroids. | 2016 | 26875009 |
| cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans. | respiratory syncytial virus (rsv) is a leading cause of respiratory tract infection in infants, causing significant morbidity and mortality. no vaccine or specific, effective treatment is currently available. a more complete understanding of the key components of effective host response to rsv and novel preventative and therapeutic interventions are urgently required. cathelicidins are host defense peptides, expressed in the inflamed lung, with key microbicidal and modulatory roles in innate hos ... | 2016 | 26873992 |
| meeting report: 4th isirv antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. | the international society for influenza and other respiratory virus diseases (isirv) held its 4th antiviral group conference at the university of texas on 2-4 june, 2015. with emerging resistance to the drugs currently licensed for treatment and prophylaxis of influenza viruses, primarily the neuraminidase inhibitor oseltamivir phosphate (tamiflu) and the m2 inhibitors amantadine and rimantadine, and the lack of effective interventions against other respiratory viruses, the 3-day programme focus ... | 2016 | 26872862 |
| best practice in the prevention and management of paediatric respiratory syncytial virus infection. | respiratory syncytial virus (rsv) infection is ubiquitous with almost all infants having been infected by 2 years of age and lifelong repeated infections common. it is the second largest cause of mortality, after malaria, in infants outside the neonatal period and causes up to 200,000 deaths per year worldwide. rsv results in clinical syndromes that include upper respiratory tract infections, otitis media, bronchiolitis (up to 80% of cases) and lower respiratory tract disease including pneumonia ... | 2016 | 27034777 |
| clinical presentation and birth outcomes associated with respiratory syncytial virus infection in pregnancy. | respiratory syncytial virus (rsv) is the most important cause of viral pneumonia in children worldwide. a maternal vaccine may protect both the mother and infant from rsv illness. the epidemiology and clinical presentation of rsv in pregnant and postpartum women is not well-described. | 2016 | 27031702 |
| healthcare workers mobile phone usage: a potential risk for viral contamination. surveillance pilot study. | mobile phones are commonly used by healthcare workers (hcw) in the working environment, as they allow instant communication and endless resource utilisation. studies suggest that mobile phones have been implicated as reservoirs of bacterial pathogens, with the potential to cause nosocomial infection. this study aimed to investigate the presence of respiratory syncytial virus, adenovirus and influenza virus on hcws mobile phones and to identify risk factors implied by hcws practice of mobile phon ... | 2016 | 27030915 |
| epidemiology of australian influenza-related paediatric intensive care unit admissions, 1997-2013. | influenza virus predictably causes an annual epidemic resulting in a considerable burden of illness in australia. children are disproportionately affected and can experience severe illness and complications, which occasionally result in death. | 2016 | 27023740 |
| resource utilization for noncardiac admissions in pediatric patients with single ventricle disease. | patients with single ventricle (sv) congenital heart disease (chd) incur high hospital costs during staged surgical palliation. health care resource utilization for noncardiac admissions in patients with sv has not been reported. this study sought to compare costs and outcomes for common noncardiac hospital admissions between patients with sv and patients without chd. hospital discharge data from the university health system consortium from january 2011 to december 2013 was queried for patients ... | 2016 | 27018934 |
| [controlling an outbreak of respiratory syncytial virus (rsv among nicu patients and the medical team]. | respiratory syncytial virus (rsv is the most common cause of respiratory infections in infants, causing bronchiolitis and pneumonia. premature infants have an increased risk for developing severe illness and even death. a monoclonal antibody vaccination named palivizumab is available for preventing rsv infection. we describe an outbreak and control of rsv infections in one of our neonatal intensive care units, involving three patients and two medical team members. | 2016 | 27012069 |
| increasing the complexity of respiratory syncytial virus infection: reactive oxygen species, dna damage, and premature senescence. | 2016 | 27008410 | |
| actin- and clathrin-dependent mechanisms regulate interferon gamma release after stimulation of human immune cells with respiratory syncytial virus. | respiratory syncytial virus (rsv) can cause recurrent and severe respiratory tract infections. cytoskeletal proteins are often involved during viral infections, either for cell entry or the initiation of the immune response. the importance of actin and clathrin dynamics for cell entry and the initiation of the cellular immune response against rsv in human immune cells is not known yet. the aim of this study was to investigate the role of actin and clathrin on cell entry of rsv and the subsequent ... | 2016 | 27004689 |
| interleukin-17 enhances the removal of respiratory syncytial virus in mice by promoting neutrophil migration and reducing interferon-gamma expression. | the aim of this study was to observe the effect of interleukin (il)-17 on early immune response and inflammation in the lungs of respiratory syncytial virus (rsv)-infected mice. specific pathogen-free balb/c mice were randomly assigned to control, rsv-infected, rsv-infected with phosphate-buffered saline, and rsv-infected + il-17 intervention groups. the rsv infection model was set up by nasal mucosa immunization. the intervention group was provided with restructured il-17 (intranasal). the vira ... | 2016 | 27050987 |
| als-008176 for respiratory syncytial virus infection. | 2016 | 27050227 | |
| als-008176 for respiratory syncytial virus infection. | 2016 | 27050226 | |
| trends in respiratory syncytial virus and bronchiolitis hospitalization rates in high-risk infants in a united states nationally representative database, 1997-2012. | respiratory syncytial virus (rsv) causes significant pediatric morbidity and is the most common cause of bronchiolitis. bronchiolitis hospitalizations declined among us infants from 2000‒2009; however, rates in infants at high risk for rsv have not been described. this study examined rsv and unspecified bronchiolitis (ub) hospitalization rates from 1997‒2012 among us high-risk infants. | 2016 | 27050095 |
| structure-guided design of small-molecule therapeutics against rsv disease. | in the united states, respiratory syncytial virus (rsv) is responsible for the majority of infant hospitalizations resulting from viral infections, as well as a leading source of pneumonia and bronchiolitis in young children and the elderly. in the absence of vaccine prophylaxis or an effective antiviral for improved disease management, the development of novel anti-rsv therapeutics is critical. several advanced drug development campaigns of the past decade have focused on blocking viral infecti ... | 2016 | 27046051 |
| seasonal dynamics of the airborne bacterial community and selected viruses in a children's daycare center. | children's daycare centers appear to be hubs of respiratory infectious disease transmission, yet there is only limited information about the airborne microbial communities that are present in daycare centers. we have investigated the microbial community of the air in a daycare center, including seasonal dynamics in the bacterial community and the presence of specific viral pathogens. we collected filters from the heating, ventilation, and air conditioning (hvac) system of a daycare center every ... | 2016 | 26942410 |
| incorporating transmission into causal models of infectious diseases for improved understanding of the effect and impact of risk factors. | conventional measures of causality (which compare risks between exposed and unexposed individuals) do not factor in the population-scale dynamics of infectious disease transmission. we used mathematical models of 2 childhood infections (respiratory syncytial virus and rotavirus) to illustrate this problem. these models incorporated 3 causal pathways whereby malnutrition could act to increase the incidence of severe infection: increasing the proportion of infected children who develop severe infe ... | 2016 | 26940116 |
| correction: correction: molecular characterization of circulating respiratory syncytial virus (rsv) genotypes in gilgit baltistan province of pakistan during 2011-2012 winter season. | 2016 | 26938668 | |
| prediction model of rsv-hospitalization in late preterm infants: an update and validation study. | new vaccines and rsv therapeutics have been developed in the past decade. with approval of these new pharmaceuticals on the horizon, new challenges lie ahead in selecting the appropriate target population. we aimed to improve a previously published prediction model for prediction of rsv-hospitalization within the first year of life. | 2016 | 26930376 |
| association between secondary thrombocytosis and viral respiratory tract infections in children. | secondary thrombocytosis (st) is frequently observed in children with a variety of clinical conditions. the leading cause of st is respiratory tract infection (rti) in children. nasopharyngeal aspirate samples were collected and assessed for common respiratory viruses. the relationships between virus infections and secondary thrombocytosis were analyzed retrospectively. the blood platelet count and the presence of respiratory viruses were determined for 3156 rti patients, and 817 (25.9%) cases w ... | 2016 | 26965460 |
| respiratory syncytial virus infection and bronchial hyperreactivity in children up to two years of age in correlation with atopy. | bronchiolitis in early childhood caused by respiratory syncytial virus (rsv) is considered to be important risk factor of the recurrent wheezing and asthma development. the aim of this study was to examine the frequency of rsv infection and atopy in children up to two years of age and to determine their correlation with bronchial hyperreactivity. | 2016 | 26964386 |
| implementation of american academy of pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital. | one hospital's implementation of revised american academy of pediatrics (aap) guidelines for palivizumab prophylaxis of respiratory syncytial virus (rsv) infection is described. | 2016 | 26953285 |